Health
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
* EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in combination with chemotherapy as a first-line treatment for non-small cell lung cancer (NSC...
2024-06-02 08:24
3160
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-06-02 08:00
4927
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...
2024-06-02 08:00
3039
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2024-06-02 08:00
3620
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cet...
2024-06-02 07:13
2912
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
CHICAGO, June 1, 2024 /PRNewswire/ -- On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for two of its products have been accepted for presentation at the 2024 American Society of Clinical Onc...
2024-06-02 03:00
1396
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
* Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors * A 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day) *...
2024-06-01 20:00
3473
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress
in the construction of its alpaca-derived nanobody discovery platform,
ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully
replaced by alpaca IGH-VDJ genes in-situ.
2024-06-01 20:00
1488
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab due...
2024-06-01 19:10
3632
Duke-NUS' largest graduating cohort celebrates diverse pathways to medicine
* The largest graduating class in Duke-NUS' history saw 90 graduates, including the first-ever Master of International Translational Medicine cohort, receive their degrees * Collectively, this cohort published 99 academic publications, underscoring Duke-NUS' role as a leader in innovation and...
2024-06-01 19:00
3391
China Jo-Jo Drugstores Announces Changes to Board of Directors
HANGZHOU, China, May 31, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that Ms. P...
2024-06-01 04:30
4997
China and South Korea Fortify Economic Ties at 2nd CISCE Roadshow
SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- On May 27, 2024, the 8th China -Japan-South Korea Business Summit convened inSeoul, South Korea, highlighted by a delegation led byRen Hongbin, Chairman of the China Council for the Promotion of International Trade. The program featured the China-So...
2024-05-31 23:24
3981
Hello Health Group (HHG) Welcomes 5i Ventures (5iV) as Leading Investor, Paving the Way for Future Growth
SINGAPORE, May 31, 2024 /PRNewswire/ -- Hello Health Group (HHG), the leading digital health and wellness platform inAsia, is pleased to announce the successful closing of theSingapore-based 5i Ventures (5iV) acquisition of a major stake in HHG. Following the transaction, 5iV will be the new lead...
2024-05-31 21:37
3876
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2
SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to ...
2024-05-31 21:16
2500
Neurophet to participate BIO USA… exploring global partnership and business
* Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development * Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for...
2024-05-31 21:00
2622
Vieworks Showcases Innovative X-ray Imaging Solutions at WCNDT (World Conference on Non-Destructive Testing) 2024
ANYANG, South Korea, May 31, 2024 /PRNewswire/ -- Vieworks, a leading innovator in x-ray imaging solution, recently marked a significant milestone by participating in the 21st World Conference on Non-Destructive Testing (WCNDT) for the first time. Held in Songdo,South Korea, WCNDT 2024 served as ...
2024-05-31 15:44
2006
Clarivate Expands Real-World Data Offering with Addition of Social Determinant of Health (SDoH) Attributes from HealthWise Data
Strategic collaboration enhances insight into patient demographics and behaviors, enabling analytical precision in addressing population health outcomes LONDON, May 31, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a str...
2024-05-31 15:00
1601
SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in acanthamoeba keratitis
ACI SANT'ANTONIO, Italy, May 31, 2024 /PRNewswire/ -- SIFI announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of AKANTIOR® (polihexanide under the international non-proprietary name),...
2024-05-31 15:00
1585
Announcement of change in the total number of votes in AB SKF
GOTHENBURG, Sweden, May 31, 2024 /PRNewswire/ -- Due to a conversion of shares from Series A to Series B in accordance with AB SKF's Articles of Association, the Company confirms the following. As per 31 May 2024, the Company's share capital amounts to SEK 1,138,377,670 and the total number of s...
2024-05-31 14:45
1529
Oy Apotti Ab Partners with uPerform to Enhance EHR Education and Support
Apotti pioneers Finnish collaboration with uPerform to scale its EHR education program and optimize support. ELKRIDGE, Md., May 31, 2024 /PRNewswire/ -- Oy Apotti Ab (Apotti) based in Helsinki, Finland, deployed a just-in-time learning platform for its Epic® -based Electronic Health Record (EHR) ...
2024-05-31 12:00
1523
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Transformation of Asia's Process Industries To Get A Boost Through Region's First Dedicated Process Technology Show
[Picked up by 279 media titles]
2024-11-12 16:00
Most Read
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5652
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5652
Sobot Introduces its All-in-One Solution at GITEX Global 2024
2024-11-12 11:00
5608
